Kairos Pharma, Ltd.
KAPA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $17,262 | $26,993 | $26,614 | $33,389 |
| - Cash | $1,272 | $93 | $437 | $73 |
| + Debt | $0 | $638 | $586 | $380 |
| Enterprise Value | $15,990 | $27,538 | $26,763 | $33,696 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$160 | -$160 | -$160 | -$98 |
| % Margin | – | – | – | – |
| EBITDA | -$1,584 | -$1,554 | -$411 | -$1,845 |
| % Margin | – | – | – | – |
| Net Income | -$2,603 | -$1,812 | -$1,050 | -$2,145 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.23 | -0.17 | -0.1 | -0.17 |
| % Growth | -35.3% | -70% | 41.2% | – |
| Operating Cash Flow | -$3,955 | $81 | -$353 | -$412 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,955 | $81 | -$353 | -$412 |